numares. |One Sample - All Answers.

2

Locations: Boston, MA;
Regensburg, GE

60+

employees of medical and
scientific disciplines

2004

Founded as a spin-off of
Regensburg University

2.5 M+

analyses worldwide with numares
technology

Mastering Metabolite Constellations. |For Precision Diagnostics.

We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that cannot be addressed by single biomarker-based medicine.

Numares has developed a versatile platform technology for developing innovative diagnostic tests based on differences in the metabolism of people with and without a particular disease.

Our diagnostic tests are based on the interpretation of biomarkers in the metabolism, with dynamics and relation to each other enabling the prediction of disease progression. These metabolite constellations create diagnostics of a new generation: non-invasive, timely and meaningful, at manageable costs.

Company Milestones

2021

FDA Submission of AXINON^® GFR(NMR)

2021

Exclusive license agreement with Oxford University

2021

numares announces FDA 510(k) Submission of AXINON System^®, a NMR platform for metabolomics-based, AI-driven Diagnostics

2021

numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics

2019

numares announces strategic collaboration with Mayo Clinic Laboratories on the development of new diagnostic tests

2018

numares completes another financing round

2018

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

2017

Launch of AXINON^® renalTX-SCORE^®-U100: first metabolomics-based IVD test for allograft rejection diagnosis after kidney transplantation

2017

Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test

2016

1,000,000 performed analyses on numares' technology platform

2016

numares completes another financing round

2015

Launch of CE-marked IVD test AXINON^® lipoFIT^®-S100 for comprehensive NMR-based lipoprotein profiling

2014

600,000 performed analyses

2014

Successful completion of studies on kidney transplantation

2014

Cooperation with a German laboratory network: commissioning of a test system for lipoprotein profiling

2013

200,000 performed analyses

2013

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

2013

Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

2010

100,000 performed analyses

2009

Certification as per EN ISO 13485:2003

As off 2005

Measurements within large studies such as GRAPHIC and KORA

2004

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)

Leadership

“With software-based diagnostic tests for our modular AXINON^® IVD System, we are focusing on improving patient care at affordable healthcare costs.”

Dr. Claus Botzler, MBA

Executive Board, CTO

“AXINON^® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize healthcare costs and maximize shareholder value.”

Florian Voss

Executive Board, COO

“Although our AXINON^® IVD System requires only minimal operator interaction, it is our claim to accompany our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Head of Service

Supervisory Board

Uwe Steinbacher

- Chairman, Supervisory Board
- Managing Partner, SHS Capital
- More than 20 years’ experience in private equity

Dr. Volker Pfahlert

- Former CEO at numares
- Previously with Roche and McKinsey

Dr. Rainer Kutzner

- Previously Managing Director of Mayfair SE
- Previously board member at Tchibo
- Supervisory board member at Puma

Kathy L. Bates, MBA

- Previously Senior Director at Mayo Clinic
- Steering committee member of numares-Mayo collaboration
- Previously with Oncospire Genetics and Roche

Dr. Gerhard Ries

- Founder and CEO of DiaMedCare
- Previously with Novartis Ciba Geigy
- Previously with McKinsey
- Founder and CEO of kineo finance AG (formerly DiaMedCare AG)

Dr. Gregory F. Heath

- Scientific Advisory Board of Everly Health
- Strategic and scientific advisor
- Previously with Roche and Illumina

Name	Purpose	Lifetime	Type	Provider
_gcl_au	Used by Google AdSense to experiment with advertisement efficiency.	3 months	HTML	Google
AMP_TOKEN	Contains a token that can be used to retrieve a Client ID from AMP Client ID service. Other possible values indicate opt-out, request in progress or an error retrieving a Client ID from AMP Client ID service.	1 year	HTML	Google
_dc_gtm_--property-id--	Used by DoubleClick (Google Tag Manager) to help identify the visitors by either age, gender or interests.	2 years	HTML	Google

“With software-based diagnostic tests for our modular AXINON® IVD System, we are focusing on improving patient care at affordable healthcare costs.”

Dr. Claus Botzler, MBA

“AXINON® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize healthcare costs and maximize shareholder value.”

Florian Voss

“Although our AXINON® IVD System requires only minimal operator interaction, it is our claim to accompany our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Uwe Steinbacher

Dr. Volker Pfahlert

Dr. Rainer Kutzner

Kathy L. Bates, MBA

Dr. Gerhard Ries

Dr. Gregory F. Heath

“With software-based diagnostic tests for our modular AXINON^® IVD System, we are focusing on improving patient care at affordable healthcare costs.”

“AXINON^® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize healthcare costs and maximize shareholder value.”

“Although our AXINON^® IVD System requires only minimal operator interaction, it is our claim to accompany our clients with the best support – beyond set-up and maintenance.”